Actively Recruiting
A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma
Led by Shanghai Hengrui Pharmaceutical Co., Ltd. · Updated on 2023-12-27
132
Participants Needed
1
Research Sites
132 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the safety, PK and preliminary anti-tumour activity of SHR-A1912 combined with other therapies in patients with B-cell non-Hodgkin 's lymphoma.
CONDITIONS
Official Title
A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than or equal to18 years old
- Eastern Cooperative Oncology Group (ECOG) performance status is 0 to 1
- Life expectancy greater than 3 months
- Histologically confirmed B-cell non-Hodgkin's lymphoma
- Relapsed and/or refractory disease after at least one line of prior systemic therapy or previously untreated (nafve cohort)
- At least one measurable nodal lesion greater than 1.5 cm or one measurable extra nodal lesion greater than 1.0 cm in its longest dimension
You will not qualify if you...
- Received autologous stem cell transplantation within 12 weeks before first study treatment
- Previously received allogeneic stem cell transplantation
- Received Car-T cell therapy within 12 weeks before first study treatment
- History of recent major surgery or severe trauma within 4 weeks before first study treatment
- Received anti-tumour treatment within 2 weeks before first study treatment
- Central nervous system infiltration
- Active infection with HBV or HCV
- History of immunodeficiency including HIV positive or other acquired or congenital immunodeficiency diseases, and active tuberculosis
- Active infection or unexplained fever greater than 38.5
- History of severe cardiovascular disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
Research Team
Z
Zhenyu Xiao, Medical Director
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here